Skip to main content


Figure 1 | Cardiovascular Diabetology

Figure 1

From: Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease?

Figure 1

Schematic depiction of the clinical outcomes of hypoadiponectinemia. Hypoadiponectinemia leads to diminished adiponectin receptors activation accompanied by increased endothelial alterations. These factors put forth several biochemical chain reactions exerting detrimental consequences via multiple pathways. These chain reactions may act reciprocally, finally conducting to serious cardiometabolic derangement.

Back to article page